Supportive Care in Cancer

, Volume 19, Supplement 1, pp 57–62

Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only)

  • Fausto Roila
  • David Warr
  • Matti Aapro
  • Rebecca A. Clark-Snow
  • Larry Einhorn
  • Richard J. Gralla
  • Jorn Herrstedt
  • Mitsue Saito
  • Maurizio Tonato
Special Article

DOI: 10.1007/s00520-010-1039-y

Cite this article as:
Roila, F., Warr, D., Aapro, M. et al. Support Care Cancer (2011) 19: 57. doi:10.1007/s00520-010-1039-y

Abstract

Purpose

An update of the recommendations for the prophylaxis of delayed emesis induced by moderately emetogenic chemotherapy discussed during the third Perugia Consensus Conference (June 2009) sponsored by MASCC–ESMO was presented. The review considered new studies published since the second consensus conference (April 2004).

Methods

An online search was used conducting PubMed and the search terms moderately, chemotherapy, and emesis with a restriction to papers in English.

Results

Overall, nine randomized controlled studies were included: four evaluating NK1 receptor antagonists, one palonosetron, and four dopamine receptor antagonists.

Conclusions

In patients receiving a combination of anthracycline plus cyclophosphamide treated with a combination of aprepitant, a 5-HT3 receptor antagonist and dexamethasone to prevent acute nausea and vomiting, aprepitant is suggested to prevent delayed emesis. In patients who do not receive aprepitant for the prophylaxis for acute emesis and in which palonosetron is recommended, a multiday oral dexamethasone is the preferred treatment for the prevention of delayed emesis. Levels of evidence and of consensus for both recommendations are moderate.

Keywords

Moderately emetogenic chemotherapyDelayed emesisNeurokinin antagonistsSerotonin antagonistsDopamine receptor antagonists

The risk of delayed emesis has been well studied in patients who have received a combination of an anthracycline and cyclophosphamide but is less clear for other agents classified as moderately emetogenic. The major prognostic factor of the frequency of delayed onset nausea and vomiting is the occurrence of acute-onset emesis. Therefore, emphasis should be placed upon the control of emesis in the first 24 h. There are, however, randomized clinical studies that show the efficacy of some antiemetic drugs specifically against delayed emesis.

Table 1 shows the current Multinational Association of Supportive Care in Cancer (MASCC), American Society of Clinical Oncology (ASCO), American Society of Health-System Pharmacists (ASHP), European Society for Medical Oncology (ESMO), and National Comprehensive Cancer Network (NCCN) practice guidelines for prophylaxis of delayed emesis following moderately emetogenic chemotherapy [15]. The recommendations range from routine use of aprepitant, corticosteroids, 5-hydroxytryptamine (5-HT3) antagonists in combination to the use of these agents only when the physician feels that the risk is high enough to warrant prophylaxis. This diversity of recommendations reflects the limited high quality of evidence and the lack of a precise definition of those groups who are at substantial risk for delayed nausea and emesis. In addition, the ASHP guidelines were published 7–10 years prior to any of the other guidelines and before any neurokinin 1 (NK1) receptor antagonist was commercially available.
Table 1

Current Consensus Guideline Recommendations

Group

Comment

Options beyond day 1

MASCC [1]

Anthracycline + cyclophosphamide (AC)

Aprepitant or dexamethasone

Moderate other than AC

Dexamethasone or a 5-HT3 antagonist

ASCO [2]

Anthracycline + cyclophosphamide (AC)

Aprepitant

Moderate other than AC

Dexamethasone or a 5-HT3 antagonist

ASHP [3]

All moderately emetogenic

5-HT3 antagonist plus dexamethasone

ESMO [4]

Anthracycline + cyclophosphamide (AC)

Aprepitant or dexamethasone

 

Moderate other than AC

Corticosteroid or a 5-HT3 antagonist

NCCN [5]

All moderately emetogenic

Aprepitant ± dexamethasone OR

Dexamethasone OR

5-HT3 antagonist ± lorazepam ± H2 blocker or proton pump inhibitor

Antiemetic studies that report results in the delayed phase of emesis are of two types: those in which the antiemetic therapies differ only beyond day 1 and those in which there is a difference starting at day 1 [6]. The latter studies are problematic to interpret when there is a difference in the control of emesis in the acute phase because the strongest prognostic factor for delayed emesis is the occurrence of nausea or emesis in the acute phase. None of the studies reviewed carried out a statistical analysis that adjusted for the differences in antiemetic control in the acute phase. Thus, studies in which antiemetic efficacy differs between the randomized groups in the acute phase can describe the frequency with which nausea and vomiting occur in the delayed phase but cannot distinguish an effect due to administration in the delayed phase from an effect due to better antiemetic control in the first 24 h.

The following is a summary of the evidence available at the time of the Perugia International Antiemetic Consensus Conference in 2004 with respect to delayed emesis in moderately emetogenic chemotherapy [6]:

Corticosteroids

Two out of three randomized trials have shown that administration of dexamethasone 4 mg bid on days 2 to 5 reduces the likelihood of delayed-onset emesis with the third study being underpowered to detect clinically important differences.

5-Hydroxytryptamine receptor antagonists

Four studies showed a trend for better control of delayed vomiting in the patients who received a 5-HT3 receptor antagonist beyond day 1, but only one showed a statistically significant difference. Two studies of palonosetron showed efficacy that was superior to a single intravenous administration of dolasetron or ondansetron in both the acute and delayed phases. The superiority in the initial 24 h could explain much of the superiority observed in the delayed phase. Less than 5% of patients received corticosteroids combined with 5-HT3 receptor antagonists and hence did not receive what is considered to be standard therapy. For that reason, guideline groups did not feel that the evidence was sufficient to endorse palonosetron as the 5-HT3 receptor antagonist of choice for preventing delayed emesis.

Dopamine receptor antagonists

Two studies provide weak evidence that the addition of a dopamine receptor antagonist may improve the control of delayed-onset nausea.

Neurokinin (NK)1 receptor antagonists

No studies were reported.

Update of literature

An online search was used conducting PubMed and the search terms moderately, chemotherapy, and emesis with a restriction to papers in English from 2004 onward. In addition, a search was done of the terms casopitant, aprepitant, granisetron, ondansetron, dolasetron, tropisetron, or palonosetron along with emesis, restricting the search to randomized trials. Abstracts were reviewed. Studies were included only if the subjects received moderately emetogenic chemotherapy as defined by MASCC. A paper that included both high and moderate semetogenicity was considered acceptable if there was a separate analysis of the moderately emetogenic group. Open-label or crossover design studies were reviewed but accepted only as supportive evidence or hypothesis-generating evidence.

NK1 receptor antagonists

Following the 2004 Perugia Consensus Conference, four studies have been reported in which NK1 receptor antagonists were used in patients receiving moderately emetogenic chemotherapy. All studies were double-blinded and three included only subjects who received an anthracycline and cyclophosphamide (AC)-based chemotherapy regimen for breast cancer. The fourth study enrolled patients scheduled to receive a single dose of at least one moderately emetogenic chemotherapy agent. All three studies with aprepitant had the same standard therapy and experimental antiemetic therapy. The study with casopitant differed slightly in design in that ondansetron was given for 3 days in both the standard and experimental groups whereas in aprepitant studies, ondansetron was continued beyond day 1 only in the standard therapy group.

In the first study, 866 patients treated with cyclophosphamide ± doxorubicin or epirubicin were randomized to receive oral aprepitant 125 mg on day 1 and 80 mg on days 2 and 3 combined with oral ondansetron 8 mg bid on day 1 only and oral dexamethasone 12 mg before chemotherapy or oral ondansetron 8 mg bid on days 1–3 and oral dexamethasone 20 mg before chemotherapy [7]. The complete response (definite as no emesis and no need for rescue medication) rate from days 1–5 as well as from day 1 was significantly superior (51% versus 42% and 76% versus 69%, respectively) with the aprepitant combination. Numerical (but not statistical) superiority was observed on days 2–4 (55% versus 49%). Although there was an absolute 17% reduction in the proportion of patients with emesis, there was no detectable effect on nausea. The results of this study led to the introduction of aprepitant in the update of the MASCC antiemetics recommendations (see Table 1).

In a much smaller study, 127 patients were randomized to the same standard and experimental therapy as in reference 7 [8]. There was a nonsignificant trend in favor of aprepitant in the primary outcome of complete response from 0–120 h (46.8% vs 41.9%) and in delayed phase (64.4% vs 57.8%) . This study was inadequately powered in that it was designed to have an 80% chance of detecting a 25% difference in the complete response rate.

A third study of the same design was carried out in 848 patients who received one or more of the following different moderately emetogenic chemotherapy agents: oxaliplatin, carboplatin, epirubicin, idarubicin, ifosfamide, irinotecan, daunorubicin, doxorubicin, cyclophosphamide (<1,500 mg/m2), or cytarabine (>1 g/m2) [9]. An anthracycline + cyclophosphamide regimen was administered in 48% of patients. No vomiting (the primary endpoint) was significantly superior with the addition of aprepitant regardless of whether patients received AC or non-AC regimens (76.2% vs 62.1% on days 1–5, 92.0% vs 83.7% on day 1, and 77.9% vs 66.8% on days 2–5. This is the only study to date that has incorporated non-AC chemotherapy. The lack of information about the distribution and dose of the non-AC chemotherapy in each arm means that it is not possible to be sure that there were no important imbalances in the emetogenicity. It should also be noted that the analysis according to type of chemotherapy (AC vs non-AC) was post hoc.

A study of similar but not identical design was carried out using the NK1 receptor antagonist, casopitant, in patients receiving AC [10]. All patients received dexamethasone 8 mg iv on day 1 and oral ondansetron 8 mg twice daily on days 1–3. Patients were randomized to a single oral dose of casopitant (150 mg on day 1), a 3-day oral casopitant arm (150 mg day 1 + 50 mg days 2–3), a 3-day iv/oral casopitant arm (90 mg iv on day 1 and 50 mg orally on days 2–3), or a control arm. Complete response on days 1–5 was significantly superior with casopitant (73%, 73%, and 74%, respectively) than with the control arm (59%). In these patients, the complete response on day 1 was similar (88%, 89%, 86%, and 85%, respectively) while on days 2–5, it was numerically, but not statistically, superior with casopitant (73%, 73%, 74%, and 59%). As with the adequately powered aprepitant study, there was a large reduction in the number of patients with emesis but no effect upon nausea.

Summary

The adequately powered studies of aprepitant and casopitant demonstrate that when added to a 5-HT3 receptor antagonist and dexamethasone, an NK1 receptor antagonist reduces the incidence of acute and delayed emesis induced by anthracycline and cyclophosphamide-based chemotherapy. At present, the evidence is insufficient to recommend routine administration of an NK1 receptor antagonist for other moderately emetogenic chemotherapy. These studies have not addressed the issue of whether an NK1 receptor antagonist needs to be administered beyond day 1 in order to improve emesis in the delayed phase. Since dexamethasone was not administered beyond 24 h, the importance of a corticosteroid in the delayed phase when an NK1 receptor antagonist is given is not known.

Palonosetron

Recently, the combination of palonosetron (0.75 mg iv) plus dexamethasone (16 mg iv) has been compared with granisetron (40 μg/kg iv) plus dexamethasone in a double-blind, randomized study involving 1,114 cancer patients who received cisplatin (57%) or AC/epirubicin and cyclophosphamide (EC) (43%) chemotherapeutic regimens [11]. All patients received dexamethasone 8 mg iv on days 2 and 3 if treated with cisplatin and 4 mg orally if treated with AC/EC. During the acute phase, a similar complete response was achieved (75.3% versus 73.3%, respectively). During the delayed phase, 56.8% of patients had a complete response in the palonosetron group compared with 44.5% in the granisetron group (p < 0.0001). Despite some shortcomings of the study (i.e., cisplatin- and non-cisplatin-treated patients were combined and doses of dexamethasone lower than those recommended for acute and delayed emesis prophylaxis), the similar results achieved in the first 24 h permit us to conclude that palonosetron provided more protection from delayed emesis than a single administration before chemotherapy of granisetron. This study does not address the issue of whether palonosetron is superior to other 5-HT3 receptor antagonists when an NK1 receptor antagonist is used as recommended by guidelines. The demonstration of superiority only in the delayed phase raises the question of whether administration of the granisetron for more than 24 h would have achieved equivalent results to palonosetron.

Summary

This study provides strong evidence that, in patients who receive moderately emetogenic chemotherapy, one dose of palonosetron, administered before chemotherapy, is more efficacious in reducing the incidence of delayed emesis than a single dose of a 5-HT3 receptor antagonist with a shorter half-life.

Dopamine receptor antagonists

Four studies have been published [1215]. In one, 691 untreated patients treated with doxorubicin-containing chemotherapy plus a 5-HT3 receptor antagonist plus dexamethasone to prevent acute emesis were randomized to receive oral prochlorperazine 10 mg tid on days 2 and 3, or an oral 5-HT3 receptor antagonist (ondansetron, granisetron, or dolasetron), or 10 mg of prochlorperazine taken as needed [12]. The primary endpoint was mean severity of delayed nausea. No difference in mean severity of nausea was observed. A major limitation of this study is that it was not double-blind.

In the second study, 232 patients who received moderately high to highly emetogenic chemotherapy and treated with ondansetron plus dexamethasone to prevent acute emesis were randomized to receive on days 2–5 15 mg of prochlorperazine spansules twice daily, or 8 mg of ondansetron tablets twice daily, or 8 mg of dexamethasone tablets twice daily [13]. This was not a double-blind study. No differences were observed between the three antiemetic treatments. The absence of superiority of the dexamethasone arm is surprising, given the results from other studies of moderately and highly emetogenic chemotherapy. This raises the question of whether there is true equivalence among the treatments or if the study, due to chance, poor compliance, or some lack of sensitivity of the methodology, simply failed to detect a true difference in efficacy.

In the third study, an open-label crossover study, 99 pretreated and chemotherapy-naive patients receiving different moderately emetogenic chemotherapy were randomized to receive sublingual metopimazine (15 mg tid) or ondansetron 8 mg bid for 5 days[14]. All patients received 48 mg of oral methylprednisolone. Treatment was successful (no vomiting and less than two episodes of nausea) in preventing delayed emesis in 73.6% during treatment with metopimazine and in 57.5%, during ondansetron. Constipation was significantly more common in those who received ondansetron. Unfortunately, it was not a blind study, and no information on the results achieved on day 1 in the two groups of patients was reported.

In the fourth study which was double-blind, 200 untreated and previously chemotherapy-treated patients receiving different moderately emetogenic chemotherapy were randomized to sublingual metopimazine 15 mg tid or sublingual ondansetron 8 mg bid for 5 days [15]. No differences were shown in complete response (53.4% vs 49.5%) or in the incidence of emesis (23.3% vs 30.9%, respectively). Gastrointestinal disorders (constipation and abdominal pain) were more frequent with ondansetron. The major limitations of this study were that treatment for preventing acute emesis was left to each investigator’s discretion, and that results achieved on day 1 for the two groups of patients were not reported.

Summary

The results of these studies do not modify the previous recommendation of a weak evidence that a dopamine receptor antagonist may improve the control of delayed emesis.

Conclusions

Patients who receive moderately emetogenic chemotherapy known to be associated with a significant incidence of delayed nausea and vomiting should receive antiemetic prophylaxis for delayed emesis.

MASCC level of confidence: high; level of consensus: high

ESMO level of evidence: I; grade of recommendation: A

In breast cancer patients receiving a combination of anthracycline plus cyclophosphamide treated with a combination of aprepitant, a 5-HT3 receptor antagonist and dexamethasone to prevent acute nausea and vomiting, aprepitant should be used to prevent delayed nausea and vomiting.

MASCC level of confidence: moderate; level of consensus: moderate

ESMO level of evidence: II; grade of recommendation: B

In patients receiving chemotherapy of moderate emetic risk which does not include a combination of anthracycline plus cyclophosphamide and in which palonosetron is recommended for the prophylaxis of acute emesis, multiday oral dexamethasone treatment is the preferred treatment for the prevention of delayed emesis.

MASCC level of confidence: moderate; level of consensus: moderate

ESMO level of evidence: II; grade of recommendation: B

The optimal duration and dose of dexamethasone have not been defined.

Further studies are required to clarify the role of more widely available dopamine receptor antagonists such as metoclopramide, prochlorperazine, or domperidone.

Acknowledgement

The 2009 MASCC/ESMO Antiemetic Guideline Update Consensus Meeting was funded by unrestricted grants from Eisai Inc, GlaxoSmithKline, Helsinn Healthcare SA, Merck & Co. Inc., and Prostrakan Group. These sources had no role in the design, conduct, or results of the conference nor in the preparation of data or this manuscript. Additionally, funding was received from the European Society of Medical Oncology (ESMO) and the Multinational Association of Supportive Care in Cancer (MASCC). MASCC organized the meeting. Individual members of either or both these organizations participated in the meeting and preparation of the manuscript.

Conflict of interest statement

The following authors either received research funding, honoraria, or have been a consultant to or an expert witness for:Roila: GSK, Helsinn, Merck; Warr: GSK. Merck; Aapro: GSK, Helsinn, Merck, Eisai, ProStrakan; Clark-Snow: No conflicts reported; Gralla: GSK, Helsinn, Merck, Eisai; Herrstedt: GSK, Helsinn, Merck; Saito: No conflicts reported; Tonato: No conflicts reported; Einhorn (wife) has been an investor in GSK

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Fausto Roila
    • 1
  • David Warr
    • 2
  • Matti Aapro
    • 3
  • Rebecca A. Clark-Snow
    • 4
  • Larry Einhorn
    • 5
  • Richard J. Gralla
    • 6
  • Jorn Herrstedt
    • 7
  • Mitsue Saito
    • 8
  • Maurizio Tonato
    • 9
  1. 1.S. Maria HospitalTerniItaly
  2. 2.Princess Margaret HospitalUniversity of TorontoTorontoCanada
  3. 3.Clinique de GenolierGenolierSwitzerland
  4. 4.University of Kansas Cancer CenterKansas CityUSA
  5. 5.Walther Cancer InstituteIndianapolisUSA
  6. 6.New York Lung Cancer AllianceNew YorkUSA
  7. 7.Odense University HospitalOdenseDenmark
  8. 8.Department of Breast OncologyJuntendo University HospitalTokyoJapan
  9. 9.Regional Cancer CentrePerugiaItaly